CORTEX PHARMACEUTICALS INC/DE/

Form 5

February 07, 2007

FORM 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL

OMB 3235-0362 Number:

January 31, Expires: 2005

1.0

Estimated average burden hours per

response...

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Washington, D.C. 20549

See Instruction Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, 1(b). Form 3 Holdings Section 17(a) of the Public Utility Holding Company Act of 1935 or Section Reported 30(h) of the Investment Company Act of 1940

Form 4

Transactions Reported

1. Name and Address of Reporting Person * ROGERS GARY ALLEN

(First)

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

CORTEX PHARMACEUTICALS

(Check all applicable)

INC/DE/ [COR] (Middle)

3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)

Director 10% Owner Other (specify X _ Officer (give title below)

below) Sr VP, Pharmaceutical Research

15241 BARRANCA PKWY (Street) 4. If Amendment, Date Original

6. Individual or Joint/Group Reporting

Filed(Month/Day/Year)

12/31/2006

(check applicable line)

IRVINE, CAÂ 92618

X Form Filed by One Reporting Person Form Filed by More than One Reporting

(City)

(Last)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)

2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if

(State)

(Zip)

3. Transaction Code (Month/Day/Year) (Instr. 8)

4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year

6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)

7. Nature of Indirect Beneficial Ownership (Instr. 4)

Amount (D) Price

(A)

or (Instr. 3 and 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 2270 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount o
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	Derivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired (A)		

Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 5

	Derivative Security				or Dispos (D) (Instr. 3, 4 and 5)					
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Options to Purchase Common Stock	\$ 3	09/05/2000	Â	A4	3,399	Â	(1)	09/05/2010	Common Stock	3,399
Options to Purchase Common Stock	\$ 0.75	12/16/2002	Â	A4	5,000	Â	(2)	12/16/2012	Common Stock	5,000
Options to Purchase Common Stock	\$ 2.76	12/09/2003	Â	A4	10,000	Â	(3)	12/09/2013	Common Stock	10,000
Options to Purchase Common Stock	\$ 2.68	12/16/2004	Â	A4	10,000	Â	(4)	12/16/2014	Common Stock	10,000
Options to Purchase Common Stock	\$ 2.35	12/01/2005	Â	A4	15,000	Â	(5)	12/01/2015	Common Stock	15,000
Options to Purchase Common Stock	\$ 1.3	12/18/2006	Â	A4	15,000	Â	(6)	12/18/2016	Common Stock	15,000

Reporting Owners

Reporting Owner Name / Address	Relationships				
1 0	Director	10% Owner	Officer	Other	
ROGERS GARY ALLEN 15241 BARRANCA PKWY IRVINE, CA 92618	Â	Â	Sr VP, Pharmaceutical Research	Â	

Reporting Owners 2

Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 5

Signatures

Maria S. Messinger, Attorney in fact 02/07/2007

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option became fully vested and exercisable as of September 5, 2003.
- (2) The option became fully vested and exercisable as of December 16, 2005.
- (3) The option became fully vested and exercisable as of December 9, 2006.
- (4) The option becomes vested and exercisable in three equal annual installments beginning on December 16, 2005.
- (5) The option becomes vested and exerciable in three equal annual installments beginning on December 1, 2006.
- (6) The option becomes vested and exercisable in three equal annual installments beginning on December 18, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3